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Abstract
Background: Acinetobacter baumannii is an increasingly worrying organism in the healthcare setting, due to its
multidrug resistance and persistence. Prolonged hospitalisation, immunocompromised patients and excessive
antibiotic exposure all contribute to increasing the risk of A. baumannii infections, which makes cancer patients a
significant risk group. This study aims to investigate the dissemination of A. baumannii at the National Cancer
Institute (NCI) in Cairo – Egypt.
Methods: All bacterial isolates were typed using Multi-locus Sequence Typing (MLST) to characterise the
epidemiology of isolates. The intrinsic OXA-51-like, and the acquired carbapanemases OXA-23, − 24/40, − 58, NDM,
IMP, and VIM were also amplified and sequenced to genetically identify mechanisms of carbapenem resistance.
Results: MLST results show a high degree of multi-clonal dissemination, with 18 different Sequence Types (STs)
identified, including 5 novel. The majority of isolates belonged to International Clone (IC) 2, and carbapenem
resistance was detected in 93% of isolates and mediated by blaOXA-23, blaOXA-58, blaNDM-1 and blaVIM-1. We also
report the presence of a resistant ST732 (OXA-378) which has been previously identified in migratory birds.
Conclusions: Multiple highly resistant clones were identified in a Cancer hospital in Cairo. It is vital that clinicians
and healthcare workers are aware of the population of A. baumannii present in order to have appropriate treatment
and infection control practices.
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Background
Acinetobacter baumannii is a problematic organism
commonly found as a persistent, multi-drug resistant or-
ganism in the hospital environment and causing a wide
range of infections in patients with prolonged hospital-
isation and severe comorbidities [1]. A. baumannii is
also one of the ESKAPE pathogens (Enterococcus fae-
cium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinotobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter sp.), which effectively “escape” the effects of
current antibacterial drugs, thereby limiting therapeutic
options [2]. Cancer patients are at a significant risk of
acquiring A. baumannii due to many risk factors such as
prolonged hospitalisation, being immunocompromised
after chemotherapy treatment, and prophylactic admin-
istration of antibiotics [3, 4]. In Egypt, several studies
have been published on the epidemiology of A. bauman-
nii and other infections in hospitalised patients, but few
studies have been published on cancer patients specific-
ally. Furthermore, previous studies from Egypt have had
limited molecular typing techniques conducted, which is
very important to get an accurate epidemiological pic-
ture and spread of the organism [4–9]. We have previ-
ously investigated the molecular epidemiology of A.
baumannii in 2013 in paediatric cancer patients in Egypt
[9]. The aim of this study was to use Multi-locus
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Sequence Typing (MLST) to characterise the epidemi-
ology of A. baumannii isolates from the National Cancer
Institute (NCI) in Cairo - Egypt, to determine the se-
quence types present, and also genetically characterise
carbapenem resistance.
Methods
Fifty-nine non-repetitive A. baumannii isolates were col-
lected in 2015 & 2016 from the NCI in Cairo, Egypt. Ini-
tial identification was performed at the NCI using
VITEK 2 (bioMérieux, Marcy l’Etoile, France). Antibiotic
susceptibility was determined using VITEK 2 and results
were interpreted according to CLSI guidelines [10]. The
gyrB multiplex method, previously described by Higgins
et al. was used to confirm the species of isolates due to
the very similar phenotypic characteristics of the A.
baumannii-calcoaleticus complex [11]. All isolates were
typed using the MLST Oxford scheme: briefly, 7 house-
keeping genes (gltA, gyrB, rpoD, cpn60, gdhB, gpi, recA)
were amplified, sequenced and assigned an allele number.
The allele numbers are combined to yield a specific se-
quence type (ST) using the pubMLST database https://
pubmlst.org/abaumannii/. The intrinsic blaOXA-51-like gene,
and the acquired carbapanemases OXA-23, − 24/40, − 58,
NDM, IMP, and VIM for all isolates were also amplified
and sequenced as mentioned previously [9, 12, 13].
Results
Fifty-five isolates were confirmed A. baumannii in
addition to 4 A. pittii (also known as Acinetobacter Gen-
omic Species (GS) 3). Ten different variants of the in-
trinsic blaOXA-51-like genes were identified: OXA-66,
OXA-69, OXA-91, OXA-94, OXA-64, OXA-51, OXA-
132, OXA-100, OXA-378, and a newly identified OXA-
510 which shares 99% identity to OXA-64, (genbank ac-
cession number KU710721.1). The 4 A. pittii isolates did
not harbour blaOXA-51-like genes.
Interestingly, 5 isolates harboured blaOXA-378 as their
intrinsic blaOXA-51-like gene, which has been reported in
stork nestlings in Poland [14], and recently in a clinical
sample of a respiratory infection in Egypt (GenBank ac-
cession number LC382028.1). No further information is
available on the isolate identified in Egypt, but the stork
nestling isolates were carbapenem sensitive, whereas the
current clinical isolates at the NCI were carbapenem re-
sistant and contained blaOXA-23. All the NCI isolates
were clonally related and assigned as ST732.
MLST typing revealed 18 different sequence types (for
30 A. baumannii isolates), 5 of which were newly
assigned (ST 1577–1581) in the current study. A. pittii
isolates were also typed with MLST and a single ST was
assigned to all four isolates: ST1089. STs were unobtain-
able for 29 isolates due to the inability to amplify/se-
quence the gdhB and/or gpi loci recombination and
insertion elements (IS) frequently disrupt these loci in
the Oxford MLST scheme [15]. The largest group was
part of International Clones (IC) 2 clone, Clonal Com-
plex (CC) 92 containing 20 isolates. Table 1 lists all the
18 STs identified in the study. Five new STs were identi-
fied (ST1577–1581) and when comparing them to other
STs in the database, ST1578 and ST1579 are Single-
locus variants (SLV) of several STs belonging to IC2/
CC92, whereas ST1581 is a Double-locus variant (DLV)
to STs in IC4/CC103. No SLV or DLV were found for
ST1577 containing OXA-132 as the intrinsic OXA-51-
like enzyme.
Carbapanem resistance was detected in 55 isolates
(93%), and only 4 isolated were sensitive to carbapenem
(Table 1). The most common class-D carbapenemase
present in the isolates was OXA-23 present in 92.7% of
A. baumannii (n = 51) and 100% of A. pittii isolates. Six
isolates co-harboured VIM-1, and 5 isolates co-
harboured NDM-1. Two isolates contained OXA-23,
NDM-1, and VIM-1. Only 2 isolates contained OXA-58,
one of which co-harboured NDM-1 (Table 1).
Discussion
A. baumannii is a problematic pathogen in many hospi-
tals and healthcare settings. Its epidemiology is particu-
larly interesting in low- and middle income countries
(LMICs) where outbreaks are commonly poly-clonal
with diverse resistance mechanisms [16–18]. The most
common global A. baumannii clone belongs to IC2/
CC92 and contains OXA-23 as the most common ac-
quired carbapenemase [19, 20]. This is typically seen in
data reported from the Middle East and Egypt in par-
ticular [6, 9, 21]. The data presented at the NCI in Cairo
shows a diverse epidemiology with several clones present
simultaneously within the hospital, as seen by the num-
ber of different STs identified, which coincide with pre-
vious reports from Egypt showing that A. baumannii is
predominantly poly-clonal and highly multi-drug resist-
ant (MDR) [9]. ST208, part of IC2, is a recurring clone
from 2013 to date, indicating the success and mainten-
ance of IC2 in Egyptian hospitals.
One of the major concerns regarding A. baumannii in-
fections is the rapid clonal spread in hospitals world-
wide. Novel strains are continuously introduced to the
clinical setting, which upon prolonged exposure to anti-
biotics, acquire and accumulate resistance genes render-
ing the infections untreatable. There is also an
uncertainty of the natural habitat and potential reser-
voirs of A. baumannii is, but it seems that environmen-
tal and zoonotic prevalence should not be overlooked.
Studies have identified A. baumannii in water, sewage
and soil samples [22], as well as animal reservoirs such
as cattle, pigs, sheep and birds [14, 23]. As reported in
this study, 5 A. baumannii ST732 isolates harboured
Al-Hassan et al. BMC Infectious Diseases          (2019) 19:829 Page 2 of 6
Table 1 Summary of all isolates, carbapenem sensitivity, intrinsic OXA-51-like, Class D and B Carbapenemases, and Sequence Type*
novel ST identified
Isolate number Species Carbapenem susceptibility OXA-51-like gene Class D-Carbapenemase
(OXA-23, − 40, − 58)
MBL ST
ABNCI - 6 A. baumannii R OXA-66 OXA-23 ST195
ABNCI - 10 A. baumannii R OXA-69 OXA-23 Unobtainable
ABNCI - 11 A. baumannii S OXA-94 ST1115
ABNCI - 12 A. baumannii R OXA-94 OXA-23 VIM-1 Unobtainable
ABNCI - 13 A. baumannii R OXA-94 OXA-23 VIM-1 ST957
ABNCI - 14 A. pittii R -ve OXA-23 ST1089
ABNCI - 15 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 2 A. baumannii R OXA-378 OXA-23 ST732
ABNCI - 25 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 26 A. baumannii R OXA-66 OXA-23 ST195
ABNCI - 3 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 29 A. baumannii S OXA-378 OXA-23 ST732
ABNCI - 30 A. pittii R -ve OXA-23 ST1089
ABNCI - 32 A. pittii R -ve OXA-23 ST1089
ABNCI - 33 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 35 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 36 A. baumannii R OXA-51-like OXA-23 ST1581*
ABNCI - 37 A. baumannii R OXA-94 OXA-23 ST1580*
ABNCI - 38 A. baumannii R OXA-64 OXA-23 Unobtainable
ABNCI - 39 A. baumannii S OXA-51-like ST1115
ABNCI - 4 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 40 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 41 A. baumannii R OXA-94 OXA-23 VIM-1 Unobtainable
ABNCI - 42 A. baumannii R OXA-51-like OXA-23 Unobtainable
ABNCI - 43 A. baumannii R OXA-51-like OXA-23 ST1100
ABNCI - 47 A. baumannii R OXA-94 OXA-23 Unobtainable
ABNCI - 48 A. baumannii R OXA-100 OXA-23 ST1100
ABNCI - 49 A. pittii R -ve OXA-23 ST1089
ABNCI - 5 A. baumannii R OXA-51-like OXA-23 Unobtainable
ABNCI - 50 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 8 A. baumannii R OXA-66 OXA-23 Unobtainable
ABNCI - 9 A. baumannii R OXA-66 OXA-23 Unobtainable
NCI-1 A. baumannii R OXA-66 OXA-23 VIM-1, NDM-1 ST1579*
NCI-2 A. baumannii R OXA-94 OXA-23 ST1580*
NCI-3 A. baumannii S OXA-510 Unobtainable
NCI-4 A. baumannii R OXA-378 OXA-23 ST732
NCI-5 A. baumannii R OXA-66 OXA-23 VIM-1, NDM-1 ST286
NCI-6 A. baumannii R OXA-66 OXA-23 NDM-1 ST1578*
NCI-7 A. baumannii R OXA-378 OXA-23 ST732
NCI-8 A. baumannii R OXA-66 OXA-23 NDM-1 Unobtainable
NCI-9 A. baumannii R OXA-378 OXA-23 ST732
NCI-10 A. baumannii R OXA-91 OXA-23 Unobtainable
NCI-11 A. baumannii R OXA-69 OXA-23 NDM-1 ST441
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OXA-378 as the intrinsic OXA-51-like enzyme, which
has been reported in stork samples from Poland and
Germany [14]. The results furthermore show the con-
tinuous introduction of novel clones into the health-
care setting, and subsequently leads us to speculate
on the role of migratory birds could have in the
dispersion of A. baumannii globally. It is important
to note however that environmental and zoonotic A.
baumannii strains are usually sensitive to carbapen-
ems, but the clones seem to acquire carbapenemases
due to the antibiotic selection pressures in the clinical
setting. In the current study the ST732/OXA-378
isolates contained OXA-23 and were carbapenem re-
sistant. According to the pubMLST database, ST732
has only been reported in Portugal, and no other data
is available. Further analysis revealed that ST732 is
neither a SLV nor DVL of any other ST in the data-
base, confirming that it is a rare clinical type.
Successful international clones, particularly IC2 are
predominantly resistant due to OXA-23, as reflected in
our data from the NCI. However, the poly-clonal dis-
semination of A. baumannii in the NCI suggests the
introduction of multiple epidemiologically diverse iso-
lates from unknown sources. OXA-510 is a new variant
in the OXA-51-like family, and although the ST was un-
obtainable, it is a DLV of the IC2/CC92, which further-
more confirms the global success of IC2. The OXA-510
isolate is sensitive to carbapanem, but may acquire mo-
bile resistance elements such as plasmids, which would
contribute to its success and spread.
Carbapenem resistance was detected in 96.3% of the
isolates. OXA-23 was the most common acquired carba-
penemase, which is similar to previous global data.
Metallo-β-lactamases VIM-1 and NDM-1 have also been
identified co-harboured by several isolated in the study.
Resistant isolates were not epidemiologically related, but
is probably mediated by the presence of several resist-
ance plasmids. Further work is underway to accurately
characterise the presence of resistance plasmids in these
isolates.
Conclusion
We hereby present a poly-clonal dissemination of A.
baumannii at the National Cancer Institute in Egypt.
93% of the isolates were carbapenem resistant and
contained OXA-23, OXA-58, NDM-1 and VIM-1. 18
different STs were identified in the study, 5 of which
are novel. The current study builds on previous work
done in 2013 which looked at the diversity of A. bau-
mannii in paediatric cancer patients in another hos-
pital in Cairo [9, 24]. The results also showed poly-
clonal dissemination, the predominance of IC2, and
very high rates of resistance indicating the capability
of A. baumannii persistence in the hospital environ-
ment through acquisition of several resistance genes.
Together with similar results from Egypt, it is import-
ant that clinicians and healthcare workers are aware
of the population of A. baumannii present in order
to have appropriate treatment and infection control
practices. It is also vital that molecular and genomic
Table 1 Summary of all isolates, carbapenem sensitivity, intrinsic OXA-51-like, Class D and B Carbapenemases, and Sequence Type*
novel ST identified (Continued)
Isolate number Species Carbapenem susceptibility OXA-51-like gene Class D-Carbapenemase
(OXA-23, − 40, − 58)
MBL ST
NCI-13 A. baumannii R OXA-51-like OXA-23 ST195
NCI-14 A. baumannii R OXA-64 OXA-23 Unobtainable
NCI-15 A. baumannii R OXA-66 OXA-23 ST208
NCI-16 A. baumannii R OXA-66 OXA-23 ST208
NCI-18 A. baumannii R OXA-51-like OXA-23 ST236
NCI-19 A. baumannii S OXA-100 ST930
NCI-20 A. baumannii R OXA-91 OXA-23 Unobtainable
NCI-23 A. baumannii S OXA-132 ST1577*
NCI-24 A. baumannii S OXA-51 Unobtainable
NCI-25 A. baumannii R OXA-66 OXA-23 ST195
NCI-26 A. baumannii R OXA-94 OXA-23 NDM-1 ST1078
NCI-27 A. baumannii R OXA-100 OXA-58 NDM-1 ST472
NCI-28 A. baumannii R OXA-51-like OXA-23 VIM-1 ST236
NCI-29 A. baumannii R OXA-66 OXA-58 NDM-1 Unobtainable
NCI-32 A. baumannii R OXA-69 OXA-23 NA
NCI-33 A. baumannii R OXA-94 NDM-1 ST1078
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technologies are implemented in order to have an
accurate epidemiological picture of Acinetobacter sp.
in order to differentiate less pathogenic species and
hospital-acquired persistors, particularly in centres
serving high risk patients.
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